Recombinant Human BTN2A1 (C-6His)

Description

EnkiLife provides the Recombinant Human BTN2A1 (C-6His) protein,aslo know as Butyrophilin subfamily 2 member A1,BTN2A1,BT2.1,BTF1, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Butyrophilin Subfamily 2 Member A1 is produced by our Mammalian expression system and the target gene encoding Gln29-Ala248 is expressed with a 6His tag at the C-terminus.Accession:Q7KYR7-2. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:25.4 KDa. Background:Butyrophilin 2A1 (BTN2A1) is an approximately widely expressed and variably glycosylated type I transmembrane glycoprotein. Mature human Butyrophilin 2A1 consisits of a 220 amino acid (aa) extracellular domain with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 258 aa cytoplasmic domain. Alternative splicing generates additional isoforms of human Butyrophilin 2A1 that lack the first Ig like domain or transmembrane segment as well as isoforms with substitutions and deletions in the cytoplasmic region. BTN2A1 is widely expressed including on colonic epithelial cells, on immune cells, and in milk fat globules. It binds to the C-type lectin DCSIGN on monocytederived dendritic cells, and this interaction can be blocked by soluble gp130 from HIV. The polymorphism of BTN2A1 has been associated with metabolic syndrome, type II diabetes mellitus, chronic kidney disease, and hypertension.